Gan-Xin Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gan-Xin Yan has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Chinmay Patel
Lankenau Medical Center and Lankenau Institute of Medical Research, Wynnewood, Pennsylvania
3 shared publicationsGuizhi Liu
First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3 shared publicationsLin Yang
The First Teaching Hospital, Xi'An Jiaotong University, Xi'An, China
3 shared publicationsPeter R. Kowey
Lankenau Medical Center and Lankenau Institute of Medical Research, Wynnewood, Pennsylvania; Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
3 shared publicationsTengxian Liu
Lankenau Institute for Medical Research, Lankenau Medical Center, Wynnewood, PA, USA
3 shared publicationsXiaolin Xue
Department of Cardiology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China
3 shared publications
Latest Publications
- Open Access
- 5 May 2017
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 6 (5)
Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation
Background: Although atrial fibrillation ( AF ) is the most common abnormal heart rhythm and its prevalence continues to rise, there is a marked paucity of effective and safe antiarrhythmic drugs for AF . This study was done to test whether combined use of dofetilide and mexiletine exhibits not only a synergistic effect on AF suppression but also a safer profile in drug‐induced ventricular proarrhythmias. Methods and Results: The effects of dofetilide plus mexiletine on atrial effective refractory period ( ERP ), AF inducibility, QT , and QT ‐related ventricular arrhythmias were studied using the isolated arterially perfused rabbit atrial and ventricular wedge preparations. Dofetilide or mexiletine alone mildly to moderately prolonged atrial ERP , but their combined use produced a markedly rate‐dependent increase in atrial ERP . Dofetilide (3 nmol/L) plus mexiletine (10 μmol/L) increased the ERP by 28.2% from 72.2±5.7 to 92.8±5.9 ms (n=9, P P p‐e prolongation, steeper QT ‐ BCL and T p‐e ‐ BCL slopes, and induced early afterdepolarizations and torsade de pointes in the ventricular wedges. Mexiletine at 10 μmol/L reduced dofetilide‐induced QT and T p‐e prolongation, QT ‐ BCL and T p‐e ‐ BCL slopes, and abolished early afterdepolarizations and torsade de pointes. Conclusions: In rabbits, combined use of dofetilide and mexiletine not only synergistically increases atrial ERP and effectively suppresses AF inducibility, but also markedly reduces QT liability and torsade de pointes risk posed by dofetilide alone.
- 5 May 2017
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 6 (5)
Open AccessSynergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation
Background: Although atrial fibrillation ( AF ) is the most common abnormal heart rhythm and its prevalence continues to rise, there is a marked paucity of effective and safe antiarrhythmic drugs for AF . This study was done to test whether combined use of dofetilide and mexiletine exhibits not only a synergistic effect on AF suppression but also a safer profile in drug‐induced ventricular proarrhythmias. Methods and Results: The effects of dofetilide plus mexiletine on atrial effective refractory period ( ERP ), AF inducibility, QT , and QT ‐related ventricular arrhythmias were studied using the isolated arterially perfused rabbit atrial and ventricular wedge preparations. Dofetilide or mexiletine alone mildly to moderately prolonged atrial ERP , but their combined use produced a markedly rate‐dependent increase in atrial ERP . Dofetilide (3 nmol/L) plus mexiletine (10 μmol/L) increased the ERP by 28.2% from 72.2±5.7 to 92.8±5.9 ms (n=9, P P p‐e prolongation, steeper QT ‐ BCL and T p‐e ‐ BCL slopes, and induced early afterdepolarizations and torsade de pointes in the ventricular wedges. Mexiletine at 10 μmol/L reduced dofetilide‐induced QT and T p‐e prolongation, QT ‐ BCL and T p‐e ‐ BCL slopes, and abolished early afterdepolarizations and torsade de pointes. Conclusions: In rabbits, combined use of dofetilide and mexiletine not only synergistically increases atrial ERP and effectively suppresses AF inducibility, but also markedly reduces QT liability and torsade de pointes risk posed by dofetilide alone.
- 1 September 2016
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 81, 161-170
How to determine cardiac ion channels targeted by drugs using the isolated rabbit ventricular wedge model
- 1 September 2016
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 81, 161-170
How to determine cardiac ion channels targeted by drugs using the isolated rabbit ventricular wedge model
- 28 June 2016
- Published by Springer Nature
- p. 15-32
J Wave Syndromes: From Bench to Bedside
- 1 August 2015
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 1 (4) , 315-322
Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures
- 1 August 2015
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 1 (4) , 315-322
Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures
- Open Access
- 5 April 2015
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 128 (7) , 969-975
J Wave Syndromes
Objective: The objective was to provide a brief history of J wave syndromes and to summarize our current understanding of their molecular, ionic, cellular mechanisms, and clinical features. We will also discuss the existing debates and further direction in basic and clinical research for J wave syndromes. Data Sources: The publications on key words of "J wave syndromes", "early repolarization syndrome (ERS)", "Brugada syndrome (BrS)" and "ST-segment elevation myocardial infarction (STEMI)" were comprehensively reviewed through search of the PubMed literatures without restriction on the publication date. Study Selection: Original articles, reviews and other literatures concerning J wave syndromes, ERS, BrS and STEMI were selected. Results: J wave syndromes were firstly defined by Yan et al. in a Chinese journal a decade ago, which represent a spectrum of variable phenotypes characterized by appearance of prominent electrocardiographic J wave including ERS, BrS and ventricular fibrillation (VF) associated with hypothermia and acute STEMI. J wave syndromes can be inherited or acquired and are mechanistically linked to amplification of the transient outward current (I to )-mediated J waves that can lead to phase 2 reentry capable of initiating VF. Conclusions: J wave syndromes are a group of newly highlighted clinical entities that share similar molecular, ionic and cellular mechanism and marked by amplified J wave on the electrocardiogram and a risk of VF. The clinical challenge ahead is to identify the patients with J wave syndromes who are at risk for sudden cardiac death and determine the alternative therapeutic strategies to reduce mortality.
- 5 April 2015
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 128 (7) , 969-975
Open AccessJ Wave Syndromes
Objective: The objective was to provide a brief history of J wave syndromes and to summarize our current understanding of their molecular, ionic, cellular mechanisms, and clinical features. We will also discuss the existing debates and further direction in basic and clinical research for J wave syndromes. Data Sources: The publications on key words of "J wave syndromes", "early repolarization syndrome (ERS)", "Brugada syndrome (BrS)" and "ST-segment elevation myocardial infarction (STEMI)" were comprehensively reviewed through search of the PubMed literatures without restriction on the publication date. Study Selection: Original articles, reviews and other literatures concerning J wave syndromes, ERS, BrS and STEMI were selected. Results: J wave syndromes were firstly defined by Yan et al. in a Chinese journal a decade ago, which represent a spectrum of variable phenotypes characterized by appearance of prominent electrocardiographic J wave including ERS, BrS and ventricular fibrillation (VF) associated with hypothermia and acute STEMI. J wave syndromes can be inherited or acquired and are mechanistically linked to amplification of the transient outward current (I to )-mediated J waves that can lead to phase 2 reentry capable of initiating VF. Conclusions: J wave syndromes are a group of newly highlighted clinical entities that share similar molecular, ionic and cellular mechanism and marked by amplified J wave on the electrocardiogram and a risk of VF. The clinical challenge ahead is to identify the patients with J wave syndromes who are at risk for sudden cardiac death and determine the alternative therapeutic strategies to reduce mortality.
- 1 January 2015
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 25 (1) , 12-21
Cellular and ionic basis of J-wave syndromes
- 1 January 2015
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 25 (1) , 12-21
Cellular and ionic basis of J-wave syndromes
- 25 February 2013
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 36 (6) , 732-740
Wenxin Keli Suppresses Ventricular Triggered Arrhythmias via Selective Inhibition of Late Sodium Current
Background: Wenxin Keli is a popular Chinese herb extract that approximately five million Asians are currently taking for the treatment of a variety of ventricular arrhythmias. However, its electrophysiological mechanisms remain poorly understood.Methods and results: The concentration‐dependent electrophysiological effects of Wenxin Keli were evaluated in the isolated rabbit left ventricular myocytes and wedge preparation. Wenxin Keli selectively inhibited late sodium current (INa) with an IC50 of 3.8 ± 0.4 mg/mL, which was significantly lower than the IC50 of 10.6 ± 0.9 mg/mL (n = 6, P < 0.05) for the fast INa. Wenxin Keli produced a small but statistically significant QT prolongation at 0.3 mg/mL, but shortened the QT and Tp–e interval at concentrations ≥1 mg/mL. Wenxin Keli increased QRS duration by 10.1% from 34.8 ± 1.0 ms to 38.3 ± 1.1 ms (n = 6, P < 0.01) at 3 mg/mL at a basic cycle length of 2,000 ms. However, its effect on the QRS duration exhibited weak use‐dependency, that is, QRS remained less changed at increased pacing rates than other classic sodium channel blockers, such as flecainide, quinidine, and lidocaine. On the other hand, Wenxin Keli at 1–3 mg/mL markedly reduced dofetilide‐induced QT and Tp–e prolongation by attenuation of its reverse use‐dependence and abolished dofetilide‐induced early afterdepolarization (EAD) in four of four left ventricular wedge preparations. It also suppressed digoxin‐induced delayed afterdepolarization (DAD) and ventricular tachycardias without changing the positive staircase pattern in contractility at 1–3 mg/mL in a separate experimental series (four of four).Conclusions: Wenxin Keli suppressed EADs, DADs, and triggered ventricular arrhythmias via selective inhibition of late INa.
- 25 February 2013
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 36 (6) , 732-740
Wenxin Keli Suppresses Ventricular Triggered Arrhythmias via Selective Inhibition of Late Sodium Current
Background: Wenxin Keli is a popular Chinese herb extract that approximately five million Asians are currently taking for the treatment of a variety of ventricular arrhythmias. However, its electrophysiological mechanisms remain poorly understood.Methods and results: The concentration‐dependent electrophysiological effects of Wenxin Keli were evaluated in the isolated rabbit left ventricular myocytes and wedge preparation. Wenxin Keli selectively inhibited late sodium current (INa) with an IC50 of 3.8 ± 0.4 mg/mL, which was significantly lower than the IC50 of 10.6 ± 0.9 mg/mL (n = 6, P < 0.05) for the fast INa. Wenxin Keli produced a small but statistically significant QT prolongation at 0.3 mg/mL, but shortened the QT and Tp–e interval at concentrations ≥1 mg/mL. Wenxin Keli increased QRS duration by 10.1% from 34.8 ± 1.0 ms to 38.3 ± 1.1 ms (n = 6, P < 0.01) at 3 mg/mL at a basic cycle length of 2,000 ms. However, its effect on the QRS duration exhibited weak use‐dependency, that is, QRS remained less changed at increased pacing rates than other classic sodium channel blockers, such as flecainide, quinidine, and lidocaine. On the other hand, Wenxin Keli at 1–3 mg/mL markedly reduced dofetilide‐induced QT and Tp–e prolongation by attenuation of its reverse use‐dependence and abolished dofetilide‐induced early afterdepolarization (EAD) in four of four left ventricular wedge preparations. It also suppressed digoxin‐induced delayed afterdepolarization (DAD) and ventricular tachycardias without changing the positive staircase pattern in contractility at 1–3 mg/mL in a separate experimental series (four of four).Conclusions: Wenxin Keli suppressed EADs, DADs, and triggered ventricular arrhythmias via selective inhibition of late INa.
- 18 June 2012
- Published by Elsevier in Heart Rhythm
- Vol. 9 (10) , 1706-1715
Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: A blinded validation
- 18 June 2012
- Published by Elsevier in Heart Rhythm
- Vol. 9 (10) , 1706-1715
Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: A blinded validation